McKesson Reports Strong Q4 & FY26 Results, Exceeds Targets, Issues Positive FY27 Guidance, and Authorizes $7.7B Share Repurchase

summarizeSummary

McKesson reported strong Q4 and full-year FY26 results, exceeding growth targets, issued positive FY27 guidance, and authorized a significant $7.7 billion share repurchase program.

check_boxKey Events

• Strong Q4 and Full Year FY26 Performance

  Consolidated revenues increased 6% to $96.3 billion for Q4 and 12% to $403.4 billion for the full year. Adjusted Earnings per Diluted Share rose 16% to $11.69 in Q4 and 18% to $39.11 for the full year, exceeding previously communicated long-range growth targets.

• Positive Fiscal 2027 Adjusted EPS Guidance

  The company established its fiscal 2027 Adjusted Earnings per Diluted Share guidance range at $43.80 to $44.60, indicating a forecasted growth of 12% to 14% compared to the prior year.

• Substantial Share Repurchase Authorization

  McKesson's Board of Directors approved a $5.0 billion increase to the share repurchase program, bringing the total authorization to $7.7 billion as of April 2026. The company also entered into a $2.25 billion accelerated share repurchase program during the fourth quarter.

• Strategic Portfolio Optimization Progress

  The company continued its strategic initiatives, including the planned separation of its Medical-Surgical Solutions segment with Apollo Global acquiring a 13% minority ownership interest, and the completion of its exit from European operations.

auto_awesomeAnalysis

McKesson Corporation delivered robust fourth-quarter and full-year fiscal 2026 results, surpassing its long-range growth targets with significant increases in revenue and adjusted EPS. The company also provided an optimistic adjusted EPS guidance for fiscal year 2027, projecting 12% to 14% growth. This strong financial performance is complemented by a substantial capital return strategy, including a new $5.0 billion increase to its share repurchase authorization, bringing the total to $7.7 billion. Investors should view this filing as a strong signal of operational excellence, continued growth, and a commitment to shareholder value, reinforcing the company's strategic direction and financial health.